{"id":"https://openalex.org/W2365508587","doi":null,"title":"Dapagliflozin,a novel sodium-glucose transporter 2 inhibitor in treatment of type 2 diabetes","display_name":"Dapagliflozin,a novel sodium-glucose transporter 2 inhibitor in treatment of type 2 diabetes","publication_year":2011,"publication_date":"2011-01-01","ids":{"openalex":"https://openalex.org/W2365508587","mag":"2365508587"},"language":"en","primary_location":{"id":"mag:2365508587","doi":null,"is_oa":false,"landing_page_url":"https://en.cnki.com.cn/Article_en/CJFDTOTAL-XYYL201106004.htm","pdf_url":null,"source":{"id":"https://openalex.org/S2764853906","display_name":"Chinese Journal of New Drugs and Clinical Remedies","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4323986928","host_organization_name":"Zhongguo Yao Xuehui Shanghai Fenhui","host_organization_lineage":["https://openalex.org/P4323986928"],"host_organization_lineage_names":["Zhongguo Yao Xuehui Shanghai Fenhui"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Chinese Journal of New Drugs and Clinical Remedies","raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100401274","display_name":"Feng Zhang","orcid":"https://orcid.org/0000-0002-6751-0377","observed_orcids":["https://orcid.org/0000-0002-6751-0377"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Feng Zhang","raw_affiliation_strings":["Shanghai Diabetes Institute,SHANGHAI 200233,China)"],"raw_orcid":"https://orcid.org/0000-0002-6751-0377","affiliations":[{"raw_affiliation_string":"Shanghai Diabetes Institute,SHANGHAI 200233,China)","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5100401274"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.31732623,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dapagliflozin","display_name":"dapagliflozin","score":1.0},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.9409999847412109},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9829999804496765},{"id":"https://openalex.org/keywords/oral-antidiabetic-drugs","display_name":"oral antidiabetic drugs","score":0.9610000252723694},{"id":"https://openalex.org/keywords/renal-glucose-reabsorption","display_name":"renal glucose reabsorption","score":0.9639999866485596},{"id":"https://openalex.org/keywords/blood-glucose-reduction","display_name":"blood glucose reduction","score":0.6179999709129333},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.8859999775886536}],"concepts":[{"id":"https://openalex.org/C2777422806","wikidata":"https://www.wikidata.org/wiki/Q409898","display_name":"Dapagliflozin","level":4,"score":0.9759613275527954},{"id":"https://openalex.org/C90466245","wikidata":"https://www.wikidata.org/wiki/Q7312490","display_name":"Renal glucose reabsorption","level":4,"score":0.8711519241333008},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.6589533090591431},{"id":"https://openalex.org/C56906281","wikidata":"https://www.wikidata.org/wiki/Q4391435","display_name":"Reabsorption","level":3,"score":0.6073709726333618},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5676838159561157},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5171101093292236},{"id":"https://openalex.org/C2781214132","wikidata":"https://www.wikidata.org/wiki/Q1136213","display_name":"Glycosuria","level":3,"score":0.5072116851806641},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5059124827384949},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5027711391448975},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.5005741119384766},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.49889612197875977},{"id":"https://openalex.org/C149011108","wikidata":"https://www.wikidata.org/wiki/Q652985","display_name":"Transporter","level":3,"score":0.43347060680389404},{"id":"https://openalex.org/C2780091579","wikidata":"https://www.wikidata.org/wiki/Q9377","display_name":"Kidney","level":2,"score":0.29162368178367615},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.13168761134147644},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2365508587","doi":null,"is_oa":false,"landing_page_url":"https://en.cnki.com.cn/Article_en/CJFDTOTAL-XYYL201106004.htm","pdf_url":null,"source":{"id":"https://openalex.org/S2764853906","display_name":"Chinese Journal of New Drugs and Clinical Remedies","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4323986928","host_organization_name":"Zhongguo Yao Xuehui Shanghai Fenhui","host_organization_lineage":["https://openalex.org/P4323986928"],"host_organization_lineage_names":["Zhongguo Yao Xuehui Shanghai Fenhui"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Chinese Journal of New Drugs and Clinical Remedies","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2773947688","https://openalex.org/W194823128","https://openalex.org/W2388523267","https://openalex.org/W2806955143","https://openalex.org/W310063286","https://openalex.org/W2146926016","https://openalex.org/W7132593803","https://openalex.org/W2392830874","https://openalex.org/W2338997164","https://openalex.org/W3028739832"],"abstract_inverted_index":{"Sodium-glucose":[0],"transporter":[1],"2(SGLT-2)is":[2],"a":[3],"transmembrane":[4],"protein,mainly":[5],"in":[6,27,76],"the":[7,15,19,28,37,58,64,88],"renal":[8],"proximal":[9],"tubule.Glucose":[10],"is":[11,40,84],"completely":[12],"reabsorbed":[13],"from":[14],"tubular":[16,20],"fluid":[17],"into":[18],"cells":[21],"by":[22,36],"SGLT-2,and":[23],"do":[24],"not":[25],"appear":[26],"urine":[29],"even":[30],"though":[31],"large":[32],"amounts":[33],"are":[34],"filtered":[35],"glomerular":[38],"capillaries.SGLT-2":[39],"responsible":[41],"for":[42],"nearly":[43],"90%renal":[44],"reabsorption":[45,65],"of":[46,60,66,91],"glucose.SGLT-2":[47],"inhibitor,a":[48],"new":[49,93],"oral":[50],"antidiabetic":[51],"drug,can":[52],"reduce":[53],"blood":[54],"glucose":[55],"through":[56],"decreasing":[57],"activity":[59],"SGLT-2":[61,71],"and":[62,74,79],"block":[63],"glucose.Clinical":[67],"trials":[68],"indicated":[69],"that":[70],"inhibitor(dapagliflozin)was":[72],"effective":[73],"safe":[75],"diabetic":[77],"patients":[78],"was":[80],"well":[81],"tolerated.SGLT-2":[82],"inhibitor":[83],"likely":[85],"to":[86],"be":[87],"future":[89],"treatment":[90],"diabetes,a":[92],"breakthrough.":[94]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}